Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Kavalactone has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Both act on GABAergic signalling, though at different points: kavalactones modulate the receptor while oral GABA has limited and debated central penetration. Anyone combining them should expect the sedative direction to be additive rather than offsetting. This is a mechanistic expectation, not something measured in a combination trial.
Valerian constituents also act on GABA-A signalling, so pairing them with kavalactones stacks two sedating inputs on the same receptor family. The combination appears in traditional calming blends. Additive sedation is the practical consequence, and it matters most for driving and for anyone already taking a sedating medicine.
Passionflower flavonoids interact with GABAergic transmission, which puts them on the same axis as kavalactones. The pairing is common in sleep and calm formulations. Expect the sedative effect to add rather than cancel.
Melatonin works through MT1 and MT2 receptors on circadian timing, a separate mechanism from GABA-A modulation. Combined, the two push sleepiness through different doors at the same time. That is why the pairing is used in night formulas and also why residual grogginess is the thing to watch.
L-theanine influences glutamate receptor binding and alpha-wave activity without strong sedation of its own. Alongside kavalactones the combination is used for a calm-without-knockout profile. The direction is additive on the calming axis.
Honokiol and magnolol are positive allosteric modulators at GABA-A, the same receptor family kavalactones modulate. Stacking two allosteric modulators at one receptor is where sedation compounds fastest. Dose conservatively if both are present.
Lemon balm constituents inhibit GABA transaminase, raising GABA availability, while kavalactones act on the receptor side. The two therefore approach the same system from opposite ends. The pairing is conventional in calming blends.
Apigenin from chamomile binds benzodiazepine sites on GABA-A, overlapping mechanistically with kavalactone modulation. The combination is old formulation practice in evening teas and capsules. Read the interaction as additive sedation.
Caffeine antagonises adenosine receptors to increase arousal while kavalactones push the opposite way through GABA-A and ion-channel effects. Neither blocks the other at a shared site, so what results is a mixed state rather than cancellation. Caffeine also shares CYP1A2 clearance with kavalactone inhibition, which can prolong caffeine's own half-life.
Silymarin itself inhibits several CYP and UGT enzymes, the same families kavalactones inhibit. Combining two inhibitors compounds the effect on anything else being cleared by those routes. The pairing appears in formulations aimed at hepatic support, but the interaction runs in the direction of slower clearance, not faster.
St John's wort induces CYP3A4 and P-glycoprotein while kavalactones inhibit several CYP isoenzymes. Taken together the net effect on any co-administered medicine becomes unpredictable in direction as well as size. Both also act centrally, which adds a second layer of uncertainty.
Kavalactones are lipophilic and dissolve poorly in water, which is why the traditional beverage relies on emulsification with plant lipids. A medium-chain triglyceride vehicle raises the dissolved fraction available for absorption. This is a delivery relationship, and it means an oil-based product and a dry capsule are not interchangeable at the same label dose.
Lecithin emulsifies the lipophilic lactone fraction into a water-dispersible form, which is the same principle behind kneading kava root in water with its native lipids. It is used to make instant powders disperse without separating. The role is delivery, not activity.
Ashwagandha is frequently placed alongside kava in stress-oriented formulations, and withanolides have their own GABAergic activity described in preclinical work. No controlled trial has tested the combination in people. Read it as formulation convention with a plausible shared axis rather than a demonstrated pairing.
Nothing specific on file for Kavalactone. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 2 we read for Kavalactone. The full linked list is below.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.